Top View
- Cannabinoid Receptors: an Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/PSM/QSM/2006.3
- A Clinical Trial Assessing the Safety and Efficacy of Taranabant, a CB1R Inverse Agonist, in Obese and Overweight Patients: a High-Dose Study
- Merck Pipeline Now Looking Slimmer with the Demise of Taranabant
- Blockade of Nicotine and Cannabinoid Reinforcement And
- Pooled Analysis of Three Randomized, Double-Blind, Placebo Controlled Trials with Rimonabant for Smoking Cessation
- Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
- The Endocannabinoid System – Current Implications for Drug Development
- Cannabinoids: from Pot to Lab Esther Papaseit1,2, Clara Pérez-Mañá1,2, Ana Pilar Pérez-Acevedo1,2, Olga Hladun1,2, M
- Central and Peripheral Consequences of the Chronic Blockade of CB1
- Regulation (EU) No 1238/2010 of the European Parliament
- Cannabis: from a Plant That Modulates Feeding
- Targeting the Endocannabinoid CB1 Receptor to Treat Body
- Cannabinoid Receptor Cannabinoid Receptor
- Cannabinoid Discrimination and Antagonism by CB1 Neutral and Inverse Agonist Antagonists
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Cannabinoid Signaling
- Current Medicinal Chemistry 1908 Researchers Havesolvedstructure the Ofmembrane the Formation Ogy Because of Theirability Tomediate the Flow of In- 1
- Experimental Weight-Loss Drug Cuts Appetite, Burns More Energy 8 January 2008
- Medicinal Chemistry of Cannabinoids
- Pharmacological Research the Endocannabinoid System: Its General Strategy of Action, Tools for Its Pharmacological Manipulation
- Population PK/PD Modeling of Efficacy and Safety of CB1R Inverse